Melatonin agonists in primary insomnia and depression-associated insomnia: Are they superior to sedative-hypnotics?
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Current pharmacological treatment of insomnia involves the use of sedative-hypnotic benzodiazepine and non-benzodiazepine drugs. Although benzodiazepines improve sleep, their multiple adverse effects hamper their application. Adverse effects include impairment of memory and cognitive functions, next-day hangover and dependence. Non-benzodiazepines are effective for initiating sleep but are not as effective as benzodiazepines for improving sleep quality or efficiency. Furthermore, their prolonged use produces adverse effects similar to those observed with benzodiazepines. Inasmuch as insomnia may be associated with decreased nocturnal melatonin, administration of melatonin is a strategy that has been increasingly used for treating insomnia. Melatonin can be effective for improving sleep quality without the adverse effects associated with hypnotic-sedatives. Ramelteon, a synthetic analog of melatonin which has a longer half life and a stronger affinity for MT1 and MT2 melatonergic receptors, has been reportedly effective for initiating and improving sleep in both adult and elderly insomniacs without showing hangover, dependence, or cognitive impairment. Insomnia is also a major complaint among patients suffering from depressive disorders and is often aggravated by conventional antidepressants especially the specific serotonin reuptake inhibitors. The novel antidepressant agomelatine, a dual action agent with affinity for melatonin MT1 and MT2 receptors and 5-HT2c antagonistic properties, constitutes a new approach to the treatment of major depressive disorders. Agomelatine ameliorates the symptoms of depression and improves the quality and efficiency of sleep. Taken together, the evidence indicates that MT1/MT2 receptor agonists like ramelteon or agomelatine may be valuable pharmacological tools for insomnia and for depression-associated insomnia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hypothalamic regulation of sleep and circadian rhythms
Saper, C. B., Scammell, T. E., & Lu, J. (2005) · Nature · doi:10.1038/nature04284 · Cited by 2,804 · cited 1×
“The sleep switch model, originally proposed by Saper and colleagues (Saper et al., 2005), states that there are “flip-flop” reciprocal inhibitions among various brain nuclei associated with sleep and wakefulness.”
Epidemiologic Study of Sleep Disturbances and Psychiatric Disorders: An Opportunity for Prevention?
Ford, D. E. (1989) · JAMA · doi:10.1001/jama.1989.03430110069030 · Cited by 2,252 · cited 1×
“The NIMH Epidemiologic Catchment Area (ECA) study of sleep disturbances and psychiatric disorders has identified sleep disturbances as a highly significant risk factor for subsequent development of depression (Ford and Kamerow, 1989).”
Nonpharmacologic Treatment of Chronic Insomnia
Morin, C. M., Hauri, P. J., Espie, C. A., Spielman, A. J., Buysse, D. J., & Bootzin, R. R. (1999) · Sleep · doi:10.1093/sleep/22.8.1134 · Cited by 888 · cited 1×
“Non pharmacologic interventions include behavioral techniques such as sleep hygiene, relaxation therapies, stimulus control, sleep restriction and cognitive therapies (Montgomery and Dennis 2004; Morin et al. 1999; Morin et al. 1999).”
Ruhé, H. G., Mason, N. S., & Schene, A. H. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001949 · Cited by 861
Sleep and depression--results from psychobiological studies: an overview
Riemann, D., Berger, M., & Voderholzer, U. (2001) · Biological Psychology · doi:10.1016/s0301-0511(01)00090-4 · Cited by 653
Krystal, A. D., Walsh, J. K., Laska, E., Caron, J., Amato, D. A., Wessel, T. C., & Roth, T. (2003) · Sleep · doi:10.1093/sleep/26.7.793 · Cited by 630
Arendt, J., & Skene, D. J. (2005) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2004.05.002 · Cited by 629 · cited 2×
“…14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 Melatonin is secreted by the pineal gland mainly at night with maximum plasma levels occurring between 02.00 to 03.00 AM (Arendt and Skene, 2005).”
InfluentialEffects of exogenous melatonin on sleep: a meta-analysis
Brzezinski, A., Vangel, M. G., Wurtman, R. J., Norrie, G., Zhdanova, I., Ben-Shushan, A., & Ford, I. (2005) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2004.06.004 · Cited by 541 · cited 2×
“metaanalysis undertaken including 17 different studies with 284 subjects, most of whom were older, concluded that melatonin is statistically effective in increasing sleep efficiency and reducing sleep onset time (Brzezinski et al., 2005).”
Self-citationBenzodiazepines and Zolpidem for Chronic Insomnia: A Meta-analysis of Treatment Efficacy
Nowell, P. D. (1997) · JAMA · doi:10.1001/jama.1997.03550240060035 · Cited by 451
Depression and insomnia: questions of cause and effect
Lustberg, L., & Reynolds, C. F. (2000) · Sleep Medicine Reviews · doi:10.1053/smrv.1999.0075 · Cited by 300 · cited 2×
“Prevention of persistent sleep disturbance may help to reduce the risk of relapse or recurrence of depression (Lustberg and Reynolds, 2000).”
Cited by
Benzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573
Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders
Ferracioli-Oda, E., Qawasmi, A., & Bloch, M. H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063773 · Cited by 483
Circadian rhythms and depression: Human psychopathology and animal models
Kronfeld-Schor, N., & Einat, H. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.020 · Cited by 166
Withdrawing Benzodiazepines in Patients With Anxiety Disorders
Lader, M., & Kyriacou, A. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-015-0642-5 · Cited by 67
Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders
Ferracioli-Oda, E., Qawasmi, A., & Bloch, M. H. (2018) · Focus · doi:10.1176/appi.focus.16101 · Cited by 18
Metadata
- Authors
- Srinivasan, V., Brzezinski, A., Pandi-Perumal, S. R., Spence, D. W., Cardinali, D. P., & Brown, G. M.
- Venue
- Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2011-06
- Volume
- 35
- Issue
- 4
- Pages
- 913-923
- ISSN
- 0278-5846 (ISSN-L)
- OpenAlex
- W2063279611
- Cited by
- 73
- References
- 23
- FWCI
- 7.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Melatonin agonists in primary insomnia and depression-associated insomnia: Are they superior to sedative-hypnotics? https://app.cochat.ai/papers/10.1016/j.pnpbp.2011.03.013
- The paper
- Srinivasan, V., Brzezinski, A., Pandi-Perumal, S. R., Spence, D. W., Cardinali, D. P., & Brown, G. M. (2011). Melatonin agonists in primary insomnia and depression-associated insomnia: Are they superior to sedative-hypnotics? Progress in Neuro-Psychopharmacology and Biological Psychiatry. https://doi.org/10.1016/j.pnpbp.2011.03.013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.